Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Assets (QoQ)Assets Growth (1y)Assets Growth (3y)Assets Growth (5y)Capital Expenditures Growth (1y)Capital Expenditures Growth (3y)Capital Expenditures Growth (5y)Cash & Equivalents (QoQ)Cash & Equivalents Growth (1y)Cash & Equivalents Growth (3y)Cash & Equivalents Growth (5y)Cash from Investing Activities (QoQ)Cash from Investing Activities Growth (1y)Cash from Investing Activities Growth (3y)Cash from Investing Activities Growth (5y)Cash from Operations (QoQ)Cash from Operations Growth (1y)Cash from Operations Growth (3y)Cash from Operations Growth (5y)EBIT (QoQ)EBIT Growth (1y)EBIT Growth (3y)EBIT Growth (5y)EBIT Margin (QoQ)EBIT Margin Growth (1y)EBIT Margin Growth (3y)EBIT Margin Growth (5y)EBITDA Margin (QoQ)EBITDA Margin Growth (1y)EBITDA Margin Growth (3y)EBITDA Margin Growth (5y)EBT (QoQ)EBT Growth (1y)EBT Growth (3y)EBT Growth (5y)EBT Margin (QoQ)EBT Margin Growth (1y)EBT Margin Growth (3y)EBT Margin Growth (5y)EPS (Basic) (QoQ)EPS (Basic) Growth (1y)EPS (Basic) Growth (3y)EPS (Basic) Growth (5y)EPS (Weighted Average and Diluted) (QoQ)EPS (Weighted Average and Diluted) Growth (1y)EPS (Weighted Average and Diluted) Growth (3y)EPS (Weighted Average and Diluted) Growth (5y)Enterprise Value (QoQ)Enterprise Value Growth (1y)Enterprise Value Growth (3y)Enterprise Value Growth (5y)FCF Margin (QoQ)FCF Margin Growth (1y)FCF Margin Growth (3y)FCF Margin Growth (5y)Free Cash Flow (QoQ)Free Cash Flow Growth (1y)Free Cash Flow Growth (3y)Free Cash Flow Growth (5y)Gross Margin (QoQ)Gross Margin Growth (1y)Gross Margin Growth (3y)Gross Profit (QoQ)Gross Profit Growth (1y)Gross Profit Growth (3y)Interest Coverage Ratio (QoQ)Interest Coverage Ratio Growth (1y)Interest Coverage Ratio Growth (3y)Interest Coverage Ratio Growth (5y)Net Cash Flow (QoQ)Net Cash Flow Growth (1y)Net Cash Flow Growth (3y)Net Cash Flow Growth (5y)Net Income (QoQ)Net Income Growth (1y)Net Income Growth (3y)Net Income Growth (5y)Net Income towards Common Stockholders (QoQ)Net Income towards Common Stockholders Growth (1y)Net Income towards Common Stockholders Growth (3y)Net Income towards Common Stockholders Growth (5y)Net Margin (QoQ)Net Margin Growth (1y)Net Margin Growth (3y)Net Margin Growth (5y)Operating Income (QoQ)Operating Income Growth (1y)Operating Income Growth (3y)Operating Income Growth (5y)Operating Margin (QoQ)Operating Margin Growth (1y)Operating Margin Growth (3y)Operating Margin Growth (5y)Profit After Tax (QoQ)Profit After Tax Growth (1y)Profit After Tax Growth (3y)Profit After Tax Growth (5y)Property, Plant & Equipment (Net) (QoQ)Property, Plant & Equipment (Net) Growth (1y)Property, Plant & Equipment (Net) Growth (3y)Property, Plant & Equipment (Net) Growth (5y)Return on Capital Employed (QoQ)Return on Capital Employed Growth (1y)Return on Capital Employed Growth (3y)Return on Capital Employed Growth (5y)Return on Equity Growth (5y)Return on Sales (QoQ)Return on Sales Growth (1y)Return on Sales Growth (3y)Return on Sales Growth (5y)Revenue (QoQ)Revenue Growth (1y)Revenue Growth (3y)Revenue Growth (5y)Share-based Compensation (QoQ)Share-based Compensation Growth (1y)Share-based Compensation Growth (3y)Share-based Compensation Growth (5y)Shareholder's Equity (QoQ)Shareholder's Equity Growth (1y)Shareholder's Equity Growth (3y)Shareholder's Equity Growth (5y)Tax Rate (QoQ)Tax Rate Growth (1y)Tax Rate Growth (3y)Tax Rate Growth (5y)Total Debt (QoQ)Total Debt Growth (1y)Total Debt Growth (3y)Total Debt Growth (5y)
Income Statement
Others
Ratios

Innoviva (INVA) EPS (Weighted Average and Diluted) Growth (1y) (2011 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) Growth (1y) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -82.39%
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -97.49%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -79.34%
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 61.45%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -7.15%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1,178.57%
10 Innoviva 1.60 Bn 992.84 Mn 75.83 Mn 400.00%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 400.00%
Sep 30, 2025 5,300.00%
Jun 30, 2025 240.00%
Mar 31, 2025 -260.87%
Sep 30, 2024 -97.96%
Jun 30, 2024 -2,850.00%
Mar 31, 2024 9.52%
Sep 30, 2023 -65.00%
Jun 30, 2023 -60.00%
Mar 31, 2023 110.00%
Sep 30, 2022 211.11%
Jun 30, 2022 -94.44%
Mar 31, 2022 -76.19%
Sep 30, 2021 246.15%
Jun 30, 2021 30.43%
Mar 31, 2021 42.37%
Dec 31, 2020 16.67%
Sep 30, 2020 -27.78%
Jun 30, 2020 102.94%
Mar 31, 2020 90.32%
Dec 31, 2019 -82.05%
Sep 30, 2019 -16.28%
Jun 30, 2019 -30.61%
Mar 31, 2019 14.81%
Dec 31, 2018 368.00%
Sep 30, 2018 104.76%
Jun 30, 2018 63.33%
Mar 31, 2018 80.00%
Dec 31, 2017 127.27%
Sep 30, 2017 61.54%
Jun 30, 2017 130.77%
Mar 31, 2017 275.00%
Dec 31, 2016 450.00%
Sep 30, 2016 425.00%
Sep 30, 2013 -18.92%
Jun 30, 2013 11.90%
Mar 31, 2013 -141.94%
Sep 30, 2012 0.00%
Jun 30, 2012 -35.48%
Mar 31, 2012 432.14%
Dec 31, 2011 -68.43%
Sep 30, 2011 -23.22%
Jun 30, 2011 -9.19%